Networking for ovarian rare tumors: a significant breakthrough improving disease management
Annals of Oncology2017cited by 35position: middledoi
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
Annals of Oncology2016cited by 59position: middledoi